Clinical Trial Detail

NCT ID NCT02265510
Title An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Incyte Corporation
Indications

Advanced Solid Tumor

Therapies

Gemcitabine

Carfilzomib

Dexamethasone

Lenalidomide

Nab-paclitaxel

Azacitidine

INCB052793

Bortezomib

Age Groups: adult

No variant requirements are available.